Clinical Trials Logo

Clinical Trial Summary

The study intends to investigate the personal experiences of semantic dementia patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal. The data collected from this study will help improve future outcomes for all semantic dementia as well as those in under-represented demographic groups.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06218732
Study type Observational
Source Power Life Sciences Inc.
Contact Michael B Gill
Phone (415) 900-4227
Email bask@withpower.com
Status Not yet recruiting
Phase
Start date February 2025
Completion date February 2027

See also
  Status Clinical Trial Phase
Completed NCT00545974 - Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Phase 4
Completed NCT04597827 - Metacognition in Semantic Dementia: Comparison With Alzheimer's Disease
Enrolling by invitation NCT04680130 - Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
Recruiting NCT03481933 - Evaluation of a Transcranial Stimulation With Direct Current on Language Disorders in Semantic Dementia N/A
Recruiting NCT03174938 - The Swedish BioFINDER 2 Study N/A
Completed NCT01623284 - PiB PET Scanning in Speech and Language Based Dementias Phase 1
Recruiting NCT05800028 - Memory and Social Interactions
Active, not recruiting NCT04881617 - Treatment for Speech and Language in Primary Progressive Aphasia N/A
Completed NCT02819700 - Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)
Recruiting NCT02964637 - Diagnosing Frontotemporal Lobar Degeneration
Completed NCT00957710 - Language Treatment for Progressive Aphasia N/A
Active, not recruiting NCT06181500 - Home-Based Exercise in Primary Progressive Aphasia (HEPPA) N/A
Recruiting NCT05184569 - Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology Phase 1